More importantly, the combination of the PLK1 inhibitor GSK and oxaliplatin effectively inhibited the growth of patient‐derived organoids from CRC patient CC0117 (Figure 3H), suggesting that PLK1 inhibition may enhance the sensitivity of CRC patients to oxaliplatin. The gene discussed is PLK1; the disease is colorectal carcinoma.